{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:41:19Z","timestamp":1759455679140,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1053\/ajkd.2001.20741","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T10:21:58Z","timestamp":1205835718000},"page":"S58-S61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S2","title":["Control of secondary hyperparathyroidism by vitamin D derivatives"],"prefix":"10.1053","volume":"37","author":[{"given":"Tilman B.","family":"Dr\u00fceke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/ajkd.2001.20741_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002239900196","article-title":"Vitamin D analogs: From renal bone disease to osteoporosis","volume":"60","author":"Kanis","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.1053\/ajkd.2001.20741_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.me.43.020192.001303","article-title":"The use of 1,25-dihydroxyvitamin D3 in early renal failure","volume":"43","author":"Goodman","year":"1992","journal-title":"Annu Rev Med"},{"key":"10.1053\/ajkd.2001.20741_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2 vitamin D3 administration in moderate renal failure: A prospective double blind trial","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"Br Med J"},{"key":"10.1053\/ajkd.2001.20741_bib5","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","article-title":"Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicenter trial)","volume":"10","author":"Ritz","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2001.20741_bib6","first-page":"245","article-title":"Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure","volume":"49","author":"Panichi","year":"1998","journal-title":"Clin Nephrol"},{"issue":"suppl 24","key":"10.1053\/ajkd.2001.20741_bib7","first-page":"S178","article-title":"Preventing renal bone disease in moderate renal failure with CaCO3 and 25 (OH) vitamin D3","volume":"33","author":"Fournier","year":"1988","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000188261","article-title":"Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients","volume":"68","author":"Fukagawa","year":"1994","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.20741_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.1995.292","article-title":"The pathogenesis of parathyroid gland hyperplasia in chronic renal failure","volume":"48","author":"Dr\u00fceke","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","article-title":"RenaGel (R), a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study","volume":"55","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib11","first-page":"216","article-title":"Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism","volume":"40","author":"Fischer","year":"1993","journal-title":"Clin Nephrol"},{"key":"10.1053\/ajkd.2001.20741_bib12","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib13","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1681\/ASN.V561344","article-title":"A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism","volume":"5","author":"Lee","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2001.20741_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000190286","article-title":"Pulse oral versus intravenous calcitriol therapy in chronic hemodialysis patients\u2014A prospective and randomized study","volume":"77","author":"Bacchini","year":"1997","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.20741_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000187887","article-title":"Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial","volume":"67","author":"Herrmann","year":"1994","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.20741_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1994.375","article-title":"Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol","volume":"46","author":"Cannella","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","article-title":"Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy","volume":"46","author":"Goodman","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000188732","article-title":"1-Alpha-hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration","volume":"71","author":"Fournier","year":"1995","journal-title":"Nephron"},{"key":"10.1053\/ajkd.2001.20741_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1\u03b1-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2001.20741_bib20","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263860194123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263860194123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:17:24Z","timestamp":1759454244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263860194123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["S027263860194123X"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2001.20741","relation":{},"ISSN":["0272-6386"],"issn-type":[{"type":"print","value":"0272-6386"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control of secondary hyperparathyroidism by vitamin D derivatives","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/ajkd.2001.20741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}